[Nephrotic syndrome due to preeclampsia: Presentation, management and clinical evolution observed in 5 years experience].

Introduction: Nephrotic syndrome (NS) is rare during pregnancy. The main cause is severe pre-eclampsia (PR). Our aim was to describe the clinical presentation, analytical features, medical management, and progress of women with NS due to PE.

[HELLP Syndrome: clinical-analytical characteristics and evolution observed in two years of experience].

Introduction: HELLP syndrome (H: hemolysis, EL: elevated liver enzymes and LP: low platelets) is a form of severe preeclampsia (PE). The syndrome can be: complete or incomplete (with three analytical criteria, or only one or two); Class i, ii or iii (according platelets < 50,000; 50,000-100,000 or > 100,000/mm); postpartum or antepartum; with early or late installation (before or after the 34nd week of gestation). We describe and analyze characteristics and evolution observed in hypertensive pregnant patients who developed HELLP.

[Utility of the neutrophil/lymphocyte ratio and the polymorphonuclear/ monomorphonuclear ratio, in the prediction of preeclampsia].

Introduction: The appearance of preeclampsia (PE) would comprise the alteration of endothelial function and activation of the inflammatory response, leading to placental hypoperfusion. The neutrophil/lymphocyte ratio (NLR) and the polymorphonuclear/monomorphonuclear ratio (PMR) could measure the underlying inflammatory component and predict the onset of the disorder.

Material And Methods: Observational, analytical, case and control study.

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.

Aim: An open-label, phase I dose-escalation trial was performed in adult patients with various solid cancers to identify the maximum tolerated dose (MTD), to assess the safety, pharmacokinetic profile and anti-tumour activity of the new prodrug CAP7.1. The prodrug is converted to its active moiety etoposide via carboxylesterases in selective cells leading to a better tolerability and higher efficacy in therapeutic resistance cells and children with refractory neuroblastoma.